| Literature DB >> 31811688 |
Abstract
BACKGROUND: We investigated the role of ventricular repolarization parameters to predict complete atrioventricular block in patients undergoing transcatheter aortic valve implantation (TAVI).Entities:
Keywords: complete atrioventricular block; transcatheter valve implantation; ventricular repolarization
Mesh:
Year: 2019 PMID: 31811688 PMCID: PMC7358893 DOI: 10.1111/anec.12734
Source DB: PubMed Journal: Ann Noninvasive Electrocardiol ISSN: 1082-720X Impact factor: 1.468
Baseline characteristics of two groups
| Baseline characteristics | Control TAVI group ( | Third degree AV block‐TAVI (+) ( |
|
|---|---|---|---|
| Age (mean) | 80.36 ± 8.7 | 81.84 ± 7.0 | .3 |
| Male/female | 74/27 | 35/14 | .5 |
| Hypertension | 83 (82%) | 35 (70%) | .28 |
| Diabetes mellitus | 36 (35%) | 16 (32%) | .4 |
| Hyperlipidemia | 21 (20%) | 4 (8%) | .09 |
| Coronary artery disease | 38 (37%) | 30 (60%) | <.05 |
| Smoke | 38 (37%) | 13 (26%) | .6 |
| Peripheral vascular disease | 2 (2%) | 5 (10%) | .2 |
| Previous cerebrovascular event | 7 (6%) | 2 (4%) | .3 |
| COPD | 20 (19%) | 13 (26%) | .7 |
| LVEF (mean %) | 53.10 ± 12.1 | 51.69 ± 13.8 | .5 |
| GFR (ml min−1 1.73 m−2) | 53.95 ± 20.1 | 54.39 ± 21.8 | .9 |
| Pulmonary artery pressure (mm Hg) | 36.64 ± 12.1 | 44.33 ± 16.3 | .8 |
| Logistic EuroSCORE (mean ± | 21.5 ± 2.8 | 20.9 ± 3.3 | .1 |
| STS score (mean ± | 10.0 ± 3.5 | 9.9 ± 4.2 | .7 |
Abbreviations: COPD, chronic obstructive pulmonary disease, GFR, glomerular filtration rate, LVEF, left ventricle ejection fraction.
Electrocardiographic findings of the study population
| Control TAVI group ( | Complete heart block‐TAVI (+) ( |
| |
|---|---|---|---|
| Heart rate (bpm) | 73.6 ± 8.9 | 87.1 ± 8.6 | <.001 |
| Tp‐e (ms) | 59.2 ± 6.1 | 74.2 ± 5.1 | <.001 |
| QTmin (ms) | 349.0 ± 3.8 | 349.3 ± 3.9 | .669 |
| QTmax (ms) | 374.8 ± 5.4 | 374.7 ± 5.6 | .912 |
| QTc (ms) | 368.1 ± 7.8 | 397.6 ± 3.4 | <.001 |
| JT (ms) | 286.0 ± 4.4 | 286.1 ± 4.4 | .874 |
| JTc (ms) | 291.1 ± 6.7 | 317.4 ± 11.3 | <.001 |
| Tp‐e/QT | 0.20 ± 0.04 | 0.28 ± 0.04 | <.001 |
| Tp‐e/QTc | 0.19 ± 0.03 | 0.29 ± 0.04 | <.001 |
| Tp‐e/JT | 0.23 ± 0.03 | 0.32 ± 0.03 | <.001 |
| Tp‐e/JTc | 0.22 ± 0.03 | 0.30 ± 0.02 | <.001 |
| QTd (ms) | 17.8 ± 3.6 | 34.4 ± 3.0 | <.001 |
| QRS (ms) | 85.9 ± 3.8 | 85.8 ± 3.9 | .943 |
JT interval (JT) was measured from the end of the QRS complex (J point) to the end of the T wave (JT end interval); QT dispersion (QTd) was determined as the difference between the maximum and minimum QT interval.
Abbreviations: bpm, beat per minute; JTc, corrected JT interval; ms, millisecond; QTc, corrected QT interval; QTmax, maximum QT; QTmin, minimum QT; Tp‐e, T peak and end interval.
Figure 1Receiver operating characteristic curve of TP‐E/JTc × 100 and TP‐E/QTc × 100
P wave amplitude, P wave duration, and PR interval
| Control TAVI group ( | Complete heart block‐TAVI (+) ( |
| |
|---|---|---|---|
| P‐amplitude (mV) | 0.13 ± 0.04 | 0.13 ± 0.04 | .89 |
| P‐duration (ms) | 105.8 ± 15.4 | 106.0 ± 13.0 | .95 |
| PR interval (ms) | 136.07 ± 20.12 | 194.00 ± 31.3 | <.001 |
Abbreviations: ms, millisecond; mV, millivolt.
Univariate and multivariate regression analyses of predictors of complete heart block in patients undergoing TAVI
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| Odds ratio (95% CI) |
| Odds ratio (95% CI) |
| |
| Age | 1.023 (0.980–1.068) | .304 | ||
| Gender | 0.912 (0.426–1.951) | .813 | ||
| PAP | 1.040 (1.014–1.067) | .002 | 0.851 (0.642–1.128) | .262 |
| Heart rate | 1.164 (1.108–1.222) | <.001 | 0.938 (0.799–1.101) | .433 |
| CAD | 2.168 (1.298–5.280) | .007 | 0.030 (0.001–2.400) | .117 |
| PVD | 1.051–30.116 | .536 | ||
| TPEQTC × 100 | 1.608 (1.380–1.875) | <.001 | 0.836 (0.603–1.159) | .282 |
| TPEJTC × 100 | 3.253 (2.034–5.203) | <.001 | 0.373 (0.130–1.072) | .067 |
| P‐duration | 1.001 (0.978–1.024) | .954 | ||
| PR interval | 1.075 (1.051–1.099) | <.001 | 0.898 (0.796–1.012) | .079 |
Abbreviations: CAD, coronary artery disease; PAP, pulmonary artery pressure; PVD, peripheral artery disease; Tp‐eJTC, T peak and end interval JTC; Tp‐eQTC, T peak and end interval QTC.